News & Insights

Stay Informed With Our Latest Updates

Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.

Insights > Keyword
Insights > Type
Global > Practices
Global > Industries
Insights > Location
Insights > Person
Insights > Date Filter
3841 Results Found

Firm News October 15, 2025

Gibson Dunn Advised Serent Capital and CallRevu on Sale of CallRevu to Astira Capital Partners

Gibson Dunn advised Serent Capital and its portfolio company CallRevu on the sale of CallRevu to Astira Capital Partners.

Firm News September 19, 2025

Gibson Dunn Advises 89bio on Its up to $3.5 Billion Sale to Roche Holdings

Gibson Dunn is advising 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, on its up to $3.5 billion sale to Roche Holdings, Inc.

Firm News July 23, 2025

Gibson Dunn Represented XOMA Royalty in the Acquisition of ESSA Pharma by XenoTherapeutics

Gibson Dunn represented XOMA Royalty Corporation in connection with the acquisition of ESSA Pharma Inc. by XenoTherapeutics, Inc.